뉴스벤징가
Eli Lilly 'Deserves' Stock Upside: Analyst
· 발표
기사 요약
Eli Lilly beats Q3 estimates on Mounjaro and Zepbound growth. Analysts lift price targets as 2026 revenue guidance jumps to $92 billion.
기사 원문에서 발췌했어요.뉴스 본문을 불러오고 있어요.
Eli Lilly beats Q3 estimates on Mounjaro and Zepbound growth. Analysts lift price targets as 2026 revenue guidance jumps to $92 billion.
기사 원문에서 발췌했어요.
댓글 —
댓글을 불러오고 있어요…